Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett maintains a 'Buy' rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $37 to $47.
September 21, 2023 | 4:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst maintains a 'Buy' rating on Revolution Medicines and raises the price target from $37 to $47.
The news of Stifel maintaining a 'Buy' rating and raising the price target for Revolution Medicines is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100